Results 191 to 200 of about 5,314 (201)

Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients

Journal of Hepatology, 2018
Kosh Agarwal, Lluís Castells Fusté, Beat Mullhaupt   +2 more
exaly  

Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

The Lancet Gastroenterology and Hepatology, 2018
Charles S Landis, Hadas Dvory-Sobol, K Rajender Reddy   +2 more
exaly  

Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection

Annals of Internal Medicine, 2015
Paul J Thuluvath
exaly  

Ribavirin/sofosbuvir/velpatasvir

Reactions Weekly, 2019
openaire   +1 more source

Sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly, 2019
openaire   +1 more source

Ribavirin/sofosbuvir/velpatasvir

Reactions Weekly, 2020
openaire   +1 more source

Sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly, 2020
openaire   +1 more source

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

Drugs, 2018
exaly  

Sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly, 2018
openaire   +1 more source

Ribavirin/sofosbuvir/velpatasvir

Reactions Weekly, 2018
openaire   +1 more source